Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The implantable cardioverter-defibrillator (ICD) is used for primary and secondary prophylaxis of sudden cardiac death in high-risk patients. While several trials have demonstrated the superiority of ICD over standard medical therapy or antiarrhythmic medication in this population, a few trials have not shown survival benefit. The Multicenter Automatic Defibrillator Implant Trial II study revealed that ICD reduces mortality in patients with ischemic cardiomyopathy. The Sudden Cardiac Death-Heart Failure Trial demonstrated that the ICD prevents sudden cardiac death and all-cause mortality in high-risk patients with moderate ischemic and nonischemic cardiomyopathy and heart failure. The ICD is also recommended for high-risk patients with inherited arrhythmia or cardiomyopathy. Cardiac resynchronization therapy reduces mortality and heart failure class as compared with optimal medical therapy in advanced heart failure. The high economic cost of widespread ICD use must also be considered. Therefore, it is prudent to identify a high-risk population who will benefit most from these devices.

Original languageEnglish
Pages (from-to)181-195
Number of pages15
JournalExpert Review of Cardiovascular Therapy
Volume7
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Cardiac Resynchronization Therapy
Implantable Defibrillators
Sudden Cardiac Death
Heart Failure
Cardiomyopathies
Mortality
Defibrillators
Population
Cardiac Arrhythmias
Economics
Costs and Cost Analysis
Equipment and Supplies
Survival
Therapeutics

Keywords

  • Cardiac resynchronization therapy
  • Implantable cardioverter-defibrillator
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

@article{a5668eb278c2454d8e60f8e9d0faa668,
title = "Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death",
abstract = "The implantable cardioverter-defibrillator (ICD) is used for primary and secondary prophylaxis of sudden cardiac death in high-risk patients. While several trials have demonstrated the superiority of ICD over standard medical therapy or antiarrhythmic medication in this population, a few trials have not shown survival benefit. The Multicenter Automatic Defibrillator Implant Trial II study revealed that ICD reduces mortality in patients with ischemic cardiomyopathy. The Sudden Cardiac Death-Heart Failure Trial demonstrated that the ICD prevents sudden cardiac death and all-cause mortality in high-risk patients with moderate ischemic and nonischemic cardiomyopathy and heart failure. The ICD is also recommended for high-risk patients with inherited arrhythmia or cardiomyopathy. Cardiac resynchronization therapy reduces mortality and heart failure class as compared with optimal medical therapy in advanced heart failure. The high economic cost of widespread ICD use must also be considered. Therefore, it is prudent to identify a high-risk population who will benefit most from these devices.",
keywords = "Cardiac resynchronization therapy, Implantable cardioverter-defibrillator, Sudden cardiac death",
author = "Mithilesh Das",
year = "2009",
month = "2",
doi = "10.1586/14779072.7.2.181",
language = "English",
volume = "7",
pages = "181--195",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death

AU - Das, Mithilesh

PY - 2009/2

Y1 - 2009/2

N2 - The implantable cardioverter-defibrillator (ICD) is used for primary and secondary prophylaxis of sudden cardiac death in high-risk patients. While several trials have demonstrated the superiority of ICD over standard medical therapy or antiarrhythmic medication in this population, a few trials have not shown survival benefit. The Multicenter Automatic Defibrillator Implant Trial II study revealed that ICD reduces mortality in patients with ischemic cardiomyopathy. The Sudden Cardiac Death-Heart Failure Trial demonstrated that the ICD prevents sudden cardiac death and all-cause mortality in high-risk patients with moderate ischemic and nonischemic cardiomyopathy and heart failure. The ICD is also recommended for high-risk patients with inherited arrhythmia or cardiomyopathy. Cardiac resynchronization therapy reduces mortality and heart failure class as compared with optimal medical therapy in advanced heart failure. The high economic cost of widespread ICD use must also be considered. Therefore, it is prudent to identify a high-risk population who will benefit most from these devices.

AB - The implantable cardioverter-defibrillator (ICD) is used for primary and secondary prophylaxis of sudden cardiac death in high-risk patients. While several trials have demonstrated the superiority of ICD over standard medical therapy or antiarrhythmic medication in this population, a few trials have not shown survival benefit. The Multicenter Automatic Defibrillator Implant Trial II study revealed that ICD reduces mortality in patients with ischemic cardiomyopathy. The Sudden Cardiac Death-Heart Failure Trial demonstrated that the ICD prevents sudden cardiac death and all-cause mortality in high-risk patients with moderate ischemic and nonischemic cardiomyopathy and heart failure. The ICD is also recommended for high-risk patients with inherited arrhythmia or cardiomyopathy. Cardiac resynchronization therapy reduces mortality and heart failure class as compared with optimal medical therapy in advanced heart failure. The high economic cost of widespread ICD use must also be considered. Therefore, it is prudent to identify a high-risk population who will benefit most from these devices.

KW - Cardiac resynchronization therapy

KW - Implantable cardioverter-defibrillator

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=64749086881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749086881&partnerID=8YFLogxK

U2 - 10.1586/14779072.7.2.181

DO - 10.1586/14779072.7.2.181

M3 - Article

C2 - 19210214

AN - SCOPUS:64749086881

VL - 7

SP - 181

EP - 195

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 2

ER -